STING1 and neoplasm: The notable pre-clinical anti-tumor effects of STING agonists have led to the development of multiple pharmacologic classes of agents, including cyclic dinucleotides, non-cyclic dinucleotides, bacterial vectors, and other unique STING agonists (28,38,39).